Belviq (lorcaserin) is a popular weight-loss drug manufactured by Eisai Inc. It’s been used by obese patients and other individuals having difficulties with losing weight and curbing hunger. A double-blind study of 12,000 people over a five-year period uncovered an increased risk of developing cancer. That prompted the U.S. Food and Drug Administration to recommend that the pharmaceutical company withdraw all Belviq and Belviz XR (lorcaserin) from the market.
REQUEST A FREE CONSULTATION
Belviq Mass Tort Campaign for Turning Leads Into Clients
TSEG can get your website in front of those affected by the dangerous complications caused by Belviq. We will review your current marketing plan and develop an effective strategy to generate leads and turn them into signed clients. Victims suffering from the harmful effects of a drug they thought they could trust deserve an attorney they can depend on. The mass tort campaigns we run can reach your target audience and let them know that you’re the type of law firm that can help them.
To learn more about us or get a free estimate for your new Belviq campaign, call TSEG today at (512) 394-7234.
What Is Belviq?
Many people use lorcaserin in conjunction with behavior changes, exercise, and a lower calorie diet to lose weight. Individuals with weight-related medical issues and those that are obese are the best targets for this drug. Lorcaserin (the generic name for Belviq) is a serotonin receptor agonist that targets the part of the brain responsible for a person’s appetite. It affects specific brain chemicals to influence appetite so that weight loss occurs.
Possible Link Between Belviq and Cancer
When the FDA first approved Belviq for use in weight loss patients in 2012, they required the manufacturer to perform a study to learn about any adverse reactions. They wanted a more thorough understanding of the potential risks people could face when taking the drug over an extended period.
Eisai Inc. conducted a five-year study, after which the FDA thoroughly reviewed the results and analyzed the data. They found an increased risk for certain cancers in the group of individuals given the actual drug. Many pharmaceuticals used for weight loss can lead to heart problems, and the primary reason for this research was to discover potential cardiovascular issues.
Although the FDA hasn’t definitively proven that there’s a link between Belviq and a higher risk of cancer, they requested that the drug company remove it from the market.
Common Side Effects of Belviq
Belviq and Belviq XR can cause various side effects ranging from mild to severe. The most common include:
- Constipation
- Dizziness
- Cough
- Fatigue
- Dry mouth
- Back pain
- Headache
- Blurry vision
- Anxiety
- Trouble falling asleep and staying asleep
- Toothache
More serious side effects associated with this drug are:
- Fever
- Confusion
- Diarrhea
- Enlarged breasts in males
- Hallucinations
- Vomiting and nausea
- Swollen feet, arms, or legs
- Thoughts of hurting oneself
- Breathing difficulties
- Dissociation
- Attention problems
- Twitching muscles or spasms
Unfortunately, some complications can have life-threatening consequences if patients don’t seek medical treatment.
Recalled Belviq and Belviq XR
Manufacturer Eisai Inc. issued a voluntary recall of Belviq and Belviq XR in February 2020 after the FDA’s recommendations. Results of their study using the drug and placebo showed that 7.7% of patients using lorcaserin developed some form of cancer compared to 7.1% in the placebo group. These findings were enough for the FDA to determine that the risks far outweighed the benefits of taking this drug.
The types of cancer associated with taking Belviq and Belviq XR include:
- Lung cancer
- Pancreatic cancer
- Colon cancer
Victims throughout the United States are suing the manufacturing company for the health problems they are now facing after taking the weight loss drug. Product liability is an area of law that holds companies liable when their products injure or kill users. TSEG can determine the right platforms to use that can get your firm noticed by Belviq victims and their families who wish to file lawsuits for compensation of their losses.
TSEG Knows How To Manage A Successful Ad Campaign
When you hire our team, we will review your ads and marketing plan to determine what’s working and what needs improvement. We analyze data and perform thorough research to learn about user behavior online. The data we find can tell us the keywords people are searching for and how to optimize your website so that your target audience sees it. They can discover who you are and the services you provide. We want to ensure they choose you over your competition.
We begin with one, two, or a combination of different digital platforms, such as Google Ads, Facebook, and YouTube. Ad placement is vital when you’re trying to garner interest from prospective clients. It’s not just about advertising your firm. It’s also about knowing when and where to run these ads so the clients you want to sign will see them.
You likely have a budget, and we will make sure we stick to it. You don’t have to spend a lot of money to effectively and efficiently grow your business. The team at TSEG has experience crafting high-quality marketing campaigns that won’t put your firm in financial jeopardy. We know the ultimate goal is to get paying clients that increase your ROI. It’s possible to do that without breaking the bank.
Call us at (512) 394-7234 today
to find out more about our lead generation and marketing campaign services or get a free estimate.
Belviq Lawsuit Updates 2024
November 2024
At this time, there are no significant news or updates in the Belviq litigation. While settlement negotiations between plaintiffs and drug manufacturer Eisai, Inc., may be ongoing, no trial dates have been confirmed.
October 2024
As of October 2024, no news updates around the Belviq litigation have been announced, and no trials have been scheduled.
September 2024
The Belviq litigation remains in a holding pattern as of September 2024. While no news has developed recently, attorneys continue to investigate cases. The litigation has stayed since May 2022 to allow settlement negotiations to occur. To date, there are no trials scheduled. A handful of cases have reached confidential settlements, but plaintiffs’ counsel report they remain optimistic about reaching a global settlement with Eisai Inc.
June 2024
Settlement negotiations are ongoing in the Belviq litigation, with no significant public developments. Attorneys are still actively investigating potential cases. The litigation remains stayed as of June 2024, with no trials scheduled.
March 2024
The Belviq litigation status remains largely unchanged. The stay implemented in May 2022 is still in effect to facilitate settlement talks. While a few cases have settled confidentially, a global settlement has not yet been reached.
December 2023
The Belviq litigation enters its 19th month of stay as of December 2023. Settlement discussions between plaintiffs’ counsel and Eisai Inc. continue behind closed doors. No trials have been scheduled, and reports indicate only a limited number of individual settlements.
September 2023
As of September 2023, settlement negotiations are progressing slowly but steadily. A handful of cases have reached confidential settlements, but the majority remain pending.
June 2023
The Belviq litigation stay continues through June 2023. Settlement talks are ongoing, with no public announcements of progress.
March 2023
As of March 2023, the Belviq litigation remains in a holding pattern. The stay implemented in May 2022 is still in effect to allow for settlement negotiations.
December 2022
The Belviq litigation stay reaches its 7-month mark in December 2022. Settlement discussions between plaintiffs’ counsel and Eisai Inc. are ongoing, but no public announcements have been made regarding progress.
September 2022
The Belviq litigation remains under the stay implemented in May to facilitate ongoing settlement negotiations.
Contact Us
TSEG works with established law firms and those that are just getting started. We can build your website from scratch or improve on your current website. When people come across your page, it’s critical that we draw them in with engaging content. We know what makes people choose to click on someone’s link or overlook it.
We can create a landing page to direct users to your firm and get them to complete a simple form to determine their eligibility for a Belviq lawsuit. They will know in an instant whether you can represent them in their case. Accessibility and user-friendly content can mean the difference between an interested client and lost revenue.
Schedule your free estimate for a comprehensive mass tort campaign for Belviq victims by calling TSEG at (512) 394-7234 right now.
During our initial meeting, we’ll review your budget and any advertising campaigns you’re currently using. We can work on a plan that is cost-effective yet yields successful results.
We know the primary goal of any mass tort campaign is to turn leads into actual clients that sign with your law firm. You can count on the team at TSEG to help you accomplish that. For help with your mass tort campaign
Call us at (512) 394-7234
FREQUENTLY ASKED QUESTIONS
What is a multi-channel approach in mass tort marketing?
A multi-channel approach in mass tort marketing involves deploying campaigns across various platforms such as digital, social media, and traditional media to ensure comprehensive market coverage and maximum engagement. This method leverages different channels to meet potential clients where they are most likely to be receptive to your messaging.
